0001193125-26-134565
SEC filingLeonaBio’s FY2025 results reflect targeted cost optimization actions tied to its strategic review, with modestly wider operating losses year-over-year.
The company expects to continue granting stock options and other equity-based awards in future periods, which will likely lead to higher stock-based compensation expense in upcoming reporting periods. LeonaBio's historical net losses, combined with expected future losses as it advances its development pipeline, will continue to have an adverse impact on total stockholders' equity for the foreseeable future. Direct costs for ongoing development programs include laboratory materials and supplies, contracted research and manufacturing, clinical trial costs, consulting fees, and other expenses required to sustain the company's research and development activities.